These are really good numbers in the US our target market, with quarter on quarter growth of 68% and half yearly growth of 43%. This would mean full year US sales of approximately US$210M.
The hospital purchasing departments will take up the generic, why would they knock back a 10% saving. The longevity is protected as there are no injectable competitors, if one attempts it the time frame and risk reward would only be contemplated on the basis of a larger market. Either way ACL wins.
Unfortunately as usual the market is not interested in this news it's all down to FDA approval.
These are really good numbers in the US our target market, with...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable